Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cannabis Bioscience International Holdings (CBIH) Debt to Equity (2023 - 2026)

Cannabis Bioscience International Holdings' Debt to Equity history spans 4 years, with the latest figure at -$0.18 for Q1 2026.

  • On a quarterly basis, Debt to Equity rose 31.64% to -$0.18 in Q1 2026 year-over-year; TTM through Feb 2026 was -$0.18, a 31.64% increase, with the full-year FY2025 number at -$0.23, up 1.79% from a year prior.
  • Debt to Equity hit -$0.18 in Q1 2026 for Cannabis Bioscience International Holdings, up from -$0.19 in the prior quarter.
  • Over the last five years, Debt to Equity for CBIH hit a ceiling of -$0.18 in Q1 2026 and a floor of -$0.45 in Q2 2023.
  • Historically, Debt to Equity has averaged -$0.25 across 4 years, with a median of -$0.23 in 2024.
  • Biggest five-year swings in Debt to Equity: skyrocketed 48.22% in 2024 and later dropped 0.18% in 2025.
  • Tracing CBIH's Debt to Equity over 4 years: stood at -$0.31 in 2023, then rose by 25.1% to -$0.23 in 2024, then grew by 16.75% to -$0.19 in 2025, then increased by 7.08% to -$0.18 in 2026.
  • Business Quant data shows Debt to Equity for CBIH at -$0.18 in Q1 2026, -$0.19 in Q4 2025, and -$0.2 in Q3 2025.